These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 33851154)

  • 1. Antibodies to the SARS-CoV-2 receptor-binding domain that maximize breadth and resistance to viral escape.
    Starr TN; Czudnochowski N; Zatta F; Park YJ; Liu Z; Addetia A; Pinto D; Beltramello M; Hernandez P; Greaney AJ; Marzi R; Glass WG; Zhang I; Dingens AS; Bowen JE; Wojcechowskyj JA; De Marco A; Rosen LE; Zhou J; Montiel-Ruiz M; Kaiser H; Tucker H; Housley MP; di Iulio J; Lombardo G; Agostini M; Sprugasci N; Culap K; Jaconi S; Meury M; Dellota E; Cameroni E; Croll TI; Nix JC; Havenar-Daughton C; Telenti A; Lempp FA; Pizzuto MS; Chodera JD; Hebner CM; Whelan SPJ; Virgin HW; Veesler D; Corti D; Bloom JD; Snell G
    bioRxiv; 2021 Apr; ():. PubMed ID: 33851154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape.
    Starr TN; Czudnochowski N; Liu Z; Zatta F; Park YJ; Addetia A; Pinto D; Beltramello M; Hernandez P; Greaney AJ; Marzi R; Glass WG; Zhang I; Dingens AS; Bowen JE; Tortorici MA; Walls AC; Wojcechowskyj JA; De Marco A; Rosen LE; Zhou J; Montiel-Ruiz M; Kaiser H; Dillen JR; Tucker H; Bassi J; Silacci-Fregni C; Housley MP; di Iulio J; Lombardo G; Agostini M; Sprugasci N; Culap K; Jaconi S; Meury M; Dellota E; Abdelnabi R; Foo SC; Cameroni E; Stumpf S; Croll TI; Nix JC; Havenar-Daughton C; Piccoli L; Benigni F; Neyts J; Telenti A; Lempp FA; Pizzuto MS; Chodera JD; Hebner CM; Virgin HW; Whelan SPJ; Veesler D; Corti D; Bloom JD; Snell G
    Nature; 2021 Sep; 597(7874):97-102. PubMed ID: 34261126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the Spike Receptor Binding Domain Class V Cryptic Epitope by an Antibody with Pan-Sarbecovirus Activity.
    Jensen JL; Sankhala RS; Dussupt V; Bai H; Hajduczki A; Lal KG; Chang WC; Martinez EJ; Peterson CE; Golub ES; Rees PA; Mendez-Rivera L; Zemil M; Kavusak E; Mayer SV; Wieczorek L; Kannan S; Doranz BJ; Davidson E; Yang ES; Zhang Y; Chen M; Choe M; Wang L; Gromowski GD; Koup RA; Michael NL; Polonis VR; Rolland M; Modjarrad K; Krebs SJ; Joyce MG
    J Virol; 2023 Jul; 97(7):e0159622. PubMed ID: 37395646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Broad Sarbecovirus Neutralizing Antibodies Obtained by Computational Design and Synthetic Library Screening.
    Yang X; Duan H; Liu X; Zhang X; Pan S; Zhang F; Gao P; Liu B; Yang J; Chi X; Yang W
    J Virol; 2023 Jul; 97(7):e0061023. PubMed ID: 37367229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of human anti-spike protein receptor binding domain antibodies on severe acute respiratory syndrome coronavirus neutralization escape and fitness.
    Sui J; Deming M; Rockx B; Liddington RC; Zhu QK; Baric RS; Marasco WA
    J Virol; 2014 Dec; 88(23):13769-80. PubMed ID: 25231316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants.
    Tai W; Wang Y; Fett CA; Zhao G; Li F; Perlman S; Jiang S; Zhou Y; Du L
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.
    Garrett ME; Galloway JG; Wolf C; Logue JK; Franko N; Chu HY; Matsen FA; Overbaugh JM
    Elife; 2022 Jan; 11():. PubMed ID: 35072628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Combination of Receptor-Binding Domain and N-Terminal Domain Neutralizing Antibodies Limits the Generation of SARS-CoV-2 Spike Neutralization-Escape Mutants.
    Haslwanter D; Dieterle ME; Wec AZ; O'Brien CM; Sakharkar M; Florez C; Tong K; Rappazzo CG; Lasso G; Vergnolle O; Wirchnianski AS; Bortz RH; Laudermilch E; Fels JM; Mengotto A; Malonis RJ; Georgiev GI; Quiroz JA; Wrapp D; Wang N; Dye KE; Barnhill J; Dye JM; McLellan JS; Daily JP; Lai JR; Herbert AS; Walker LM; Chandran K; Jangra RK
    mBio; 2021 Oct; 12(5):e0247321. PubMed ID: 34607456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations.
    Muecksch F; Weisblum Y; Barnes CO; Schmidt F; Schaefer-Babajew D; Wang Z; C Lorenzi JC; Flyak AI; DeLaitsch AT; Huey-Tubman KE; Hou S; Schiffer CA; Gaebler C; Da Silva J; Poston D; Finkin S; Cho A; Cipolla M; Oliveira TY; Millard KG; Ramos V; Gazumyan A; Rutkowska M; Caskey M; Nussenzweig MC; Bjorkman PJ; Hatziioannou T; Bieniasz PD
    Immunity; 2021 Aug; 54(8):1853-1868.e7. PubMed ID: 34331873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies.
    Muecksch F; Weisblum Y; Barnes CO; Schmidt F; Schaefer-Babajew D; Lorenzi JCC; Flyak AI; DeLaitsch AT; Huey-Tubman KE; Hou S; Schiffer CA; Gaebler C; Wang Z; Da Silva J; Poston D; Finkin S; Cho A; Cipolla M; Oliveira TY; Millard KG; Ramos V; Gazumyan A; Rutkowska M; Caskey M; Nussenzweig MC; Bjorkman PJ; Hatziioannou T; Bieniasz PD
    bioRxiv; 2021 Mar; ():. PubMed ID: 33758864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies.
    Jette CA; Cohen AA; Gnanapragasam PNP; Muecksch F; Lee YE; Huey-Tubman KE; Schmidt F; Hatziioannou T; Bieniasz PD; Nussenzweig MC; West AP; Keeffe JR; Bjorkman PJ; Barnes CO
    Cell Rep; 2021 Sep; 36(13):109760. PubMed ID: 34534459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern.
    Yuan M; Chen X; Zhu Y; Dong X; Liu Y; Qian Z; Ye L; Liu P
    J Virol; 2022 Aug; 96(16):e0077522. PubMed ID: 35916510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Computational Analysis of Mutations in the Receptor-Binding Domain of SARS-CoV-2 Spike and Their Effects on Antibody Binding.
    Bozdaganyan ME; Shaitan KV; Kirpichnikov MP; Sokolova OS; Orekhov PS
    Viruses; 2022 Jan; 14(2):. PubMed ID: 35215888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defining a de novo non-RBM antibody as RBD-8 and its synergistic rescue of immune-evaded antibodies to neutralize Omicron SARS-CoV-2.
    Rao X; Zhao R; Tong Z; Guo S; Peng W; Liu K; Li S; Wu L; Tong J; Chai Y; Han P; Wang F; Jia P; Li Z; Zhao X; Li D; Zhang R; Zhang X; Zou W; Li W; Wang Q; Gao GF; Wu Y; Dai L; Gao F
    Proc Natl Acad Sci U S A; 2023 Dec; 120(52):e2314193120. PubMed ID: 38109549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.
    Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y
    Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural mechanism of SARS-CoV-2 neutralization by two murine antibodies targeting the RBD.
    Errico JM; Zhao H; Chen RE; Liu Z; Case JB; Ma M; Schmitz AJ; Rau MJ; Fitzpatrick JAJ; Shi PY; Diamond MS; Whelan SPJ; Ellebedy AH; Fremont DH
    Cell Rep; 2021 Oct; 37(4):109881. PubMed ID: 34655519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combating the SARS-CoV-2 Omicron (BA.1) and BA.2 with potent bispecific antibodies engineered from non-Omicron neutralizing antibodies.
    Wang Y; Zhang X; Ma Y; Wang Y; Zhan W; Zheng Q; Zhang M; Ji P; Liu M; Liu Q; Sun T; Zhu T; Wen Y; Sun L; Zhao J; Wu F; Chen Z; Huang J
    Cell Discov; 2022 Oct; 8(1):104. PubMed ID: 36207299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationally designed immunogens enable immune focusing to the SARS-CoV-2 receptor binding motif.
    Hauser BM; Sangesland M; Denis KJS; Windsor IW; Feldman J; Lam EC; Kannegieter T; Balazs AB; Lingwood D; Schmidt AG
    bioRxiv; 2021 Jul; ():. PubMed ID: 33758851
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.